Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

1.

[Diagnosis and treatment of neuromyelitis optica.]

Nielsen HH, Ravnborg M, Illes Z.

Ugeskr Laeger. 2014 Jun 23;176(26). pii: V02130104. Danish.

PMID:
25294570
[PubMed - as supplied by publisher]
2.

Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment.

Jensen H, Ravnborg M, Mamoei S, Dalgas U, Stenager E.

Mult Scler. 2014 Dec;20(14):1872-80. doi: 10.1177/1352458514533844. Epub 2014 May 22.

PMID:
24852920
[PubMed - in process]
3.

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients.

Sorensen PS, Koch-Henriksen N, Petersen T, Ravnborg M, Oturai A, Sellebjerg F.

J Neurol. 2014 Jun;261(6):1170-7. doi: 10.1007/s00415-014-7325-8. Epub 2014 Apr 12.

PMID:
24728334
[PubMed - in process]
4.

4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review.

Jensen HB, Ravnborg M, Dalgas U, Stenager E.

Ther Adv Neurol Disord. 2014 Mar;7(2):97-113. doi: 10.1177/1756285613512712. Review.

PMID:
24587826
[PubMed]
Free PMC Article
5.

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group.

Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.

PMID:
24461574
[PubMed - indexed for MEDLINE]
6.

Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.

Svenningsson A, Falk E, Celius EG, Fuchs S, Schreiber K, Berkö S, Sun J, Penner IK; Tynergy Trial Investigators.

PLoS One. 2013;8(3):e58643. doi: 10.1371/journal.pone.0058643. Epub 2013 Mar 21.

PMID:
23555589
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.

Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Preziosa P, Ravnborg M, Rieckmann P, Rocca MA, Wynn D, Young C, Filippi M.

Mult Scler. 2013 Jul;19(8):1074-83. doi: 10.1177/1352458512469695. Epub 2012 Dec 12.

PMID:
23234810
[PubMed - indexed for MEDLINE]
8.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
[PubMed - indexed for MEDLINE]
9.

Rehabilitation therapy in MS; a short-term, expensive, placebo.

Ravnborg M.

Mult Scler. 2012 Oct;18(10):1377-8. No abstract available.

PMID:
23014626
[PubMed - indexed for MEDLINE]
10.

Progression and CSF Inflammation after Eradication of Oligoclonal Bands in an MS Patient Treated with Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma.

Braendstrup P, Langkilde AR, Schreiber K, Ravnborg M, Sellebjerg F, Vindeløv L.

Case Rep Neurol. 2012 May;4(2):101-6. doi: 10.1159/000339738. Epub 2012 Jun 12.

PMID:
22740825
[PubMed]
Free PMC Article
11.

[Aminopyridines for symptomatic treatment of multiple sclerosis].

Jensen HB, Stenager E, Ravnborg MH.

Ugeskr Laeger. 2011 Dec 12;173(50):3259-63. Danish.

PMID:
22153210
[PubMed - indexed for MEDLINE]
12.

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group.

N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.

PMID:
21991951
[PubMed - indexed for MEDLINE]
Free Article
13.

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.

Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J.

Lancet Neurol. 2011 Aug;10(8):745-58. doi: 10.1016/S1474-4422(11)70149-1. Review.

PMID:
21777829
[PubMed - indexed for MEDLINE]
14.

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB; SIMCOMBIN study investigators.

Lancet Neurol. 2011 Aug;10(8):691-701. doi: 10.1016/S1474-4422(11)70144-2.

PMID:
21742556
[PubMed - indexed for MEDLINE]
15.

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.

Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.

Lancet Neurol. 2010 Jul;9(7):672-80. doi: 10.1016/S1474-4422(10)70132-0. Epub 2010 Jun 9. Erratum in: Lancet Neurol. 2010 Aug;9(8):759.

PMID:
20542736
[PubMed - indexed for MEDLINE]
16.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661
[PubMed - indexed for MEDLINE]
17.

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group.

Lancet. 2009 Oct 31;374(9700):1503-11. doi: 10.1016/S0140-6736(09)61259-9. Epub 2009 Oct 6. Erratum in: Lancet. 2010 Apr 24;375(9724):1436.

PMID:
19815268
[PubMed - indexed for MEDLINE]
18.

Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.

Hesse D, Frederiksen JL, Koch-Henriksen N, Schreiber K, Stenager E, Heltberg A, Ravnborg M, Bendtzen K, Sellebjerg F, Sorensen PS.

Eur J Neurol. 2009 Jan;16(1):43-7. doi: 10.1111/j.1468-1331.2008.02336.x.

PMID:
19087149
[PubMed - indexed for MEDLINE]
19.

Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.

Ravnborg M, Bendtzen K, Christensen O, Jensen PE, Hesse D, Tovey MG, Sørensen PS.

Mult Scler. 2009 Mar;15(3):323-8. doi: 10.1177/1352458508099476. Epub 2008 Nov 21.

PMID:
19028832
[PubMed - indexed for MEDLINE]
20.

[Magnetic resonance imaging in the diagnosis and follow-up of multiple sclerosis].

Mathiesen HK, Ravnborg M, Sørensen PS.

Ugeskr Laeger. 2008 Aug 18;170(34):2579-81. Danish.

PMID:
18761844
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk